Human Recombinant Insulin Market - Global Trends, and Forecast, 2022 - 2028

Human Recombinant Insulin Market - Global Trends, and Forecast, 2022 - 2028

Recombinant human insulin is the synthetic insulin, developed using recombinant DNA technology by growing insulin proteins within Escherichia coli. Recombinant human insulin has a faster onset of action and lower immunogenicity than other types of insulin such as pork or beef insulin. Human insulin is available primarily in two forms: a short acting (regular) form and an intermediate acting (NPH) form. Moreover, the premixed human insulin is formed by combining two types of insulin, among which one is controls blood sugar level throughout the day, while second type of insulin helps to control blood sugar at meal times. Human recombinant insulin market is gaining traction due to development of biosimilar analogue of insulin, worldwide.
Market Dynamics
Sedentary and unhealthy lifestyle, binge eating, obesity, impaired glucose tolerance, diabetes family history, and increased insulin resistance are some of the risk factors for developing diabetes among the global population. Moreover, increasing number of diabetic population, and growing research and development (R&D) studies in human recombinant insulin to introduce improved version of insulin in the market is expected to boost the growth of human recombinant insulin market in near future. Key manufactures are launching innovative and improved human recombinant insulin in the market to fulfill the increasing demand for insulin. According to the Addressing the Challenge and Constraints of Insulin Sources and Supply (ACCISS): 2016 report, global insulin market is largely dominated by three pharmaceutical companies: Novo Nordisk A/S, Sanofi S.A. and Eli Lilly and Company. Furthermore, Southeast Asia and Latin America accounts with higher number of smaller human recombinant insulin manufactures, than other regions.
Key features of the study:
This report provides in-depth analysis of human recombinant insulin in pharmaceutical sector and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global human recombinant insulin market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans
Key companies covered as a part of this study include Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Julphar Gulf Pharmaceutical Industries, Biocon Limited, Bioton S.A., Gan & Lee Pharmaceuticals, Ltd., Zhuhai United Laboratories Co., Ltd., Wanbang Biopharmaceuticals Co., Ltd. and Dongbao Enterprise Group Co., Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion and marketing tactics
The global human recombinant insulin market report caters to various stakeholders in this industry including investors, suppliers, human recombinant insulin manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision making through the various strategy matrices used in analyzing the human recombinant insulin market.
Detailed Segmentation:
Global Human Recombinant Insulin Market, By Product Type:
Rapid-Acting Human Insulin
Short-Acting Human Insulin
Intermediate-Acting Human Insulin
Long-Acting Human Insulin
Premixed Human Insulin
Global Human Recombinant Insulin Market, By Brand:
Humalog
Novolog
Apidra
Humulin R
Novolin R
Humulin N
Novolin N
Levemir
Lantus
Humalog Mix
Novolog Mix
Others
Global Human Recombinant Insulin Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Human Recombinant Insulin Market, By Region:
North America
By Country:
U.S.
Canada
By Product Type:
Rapid-Acting Human Insulin
Short-Acting Human Insulin
Intermediate-Acting Human Insulin
Long-Acting Human Insulin
Premixed Human Insulin
By Brand
Humalog
Novolog
Apidra
Humulin R
Novolin R
Humulin N
Novolin N
Levemir
Lantus
Humalog Mix
Novolog Mix
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Europe
By Country:
Germany
France
Italy
UK
Spain
Russia
Rest of Europe
By Product Type:
Rapid-Acting Human Insulin
Short-Acting Human Insulin
Intermediate-Acting Human Insulin
Long-Acting Human Insulin
Premixed Human Insulin
By Brand
Humalog
Novolog
Apidra
Humulin R
Novolin R
Humulin N
Novolin N
Levemir
Lantus
Humalog Mix
Novolog Mix
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Asia Pacific
By Country:
China
India
Japan
South Korea
Australia
Rest of Asia Pacific
By Product Type:
Rapid-Acting Human Insulin
Short-Acting Human Insulin
Intermediate-Acting Human Insulin
Long-Acting Human Insulin
Premixed Human Insulin
By Brand
Humalog
Novolog
Apidra
Humulin R
Novolin R
Humulin N
Novolin N
Levemir
Lantus
Humalog Mix
Novolog Mix
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Product Type:
Rapid-Acting Human Insulin
Short-Acting Human Insulin
Intermediate-Acting Human Insulin
Long-Acting Human Insulin
Premixed Human Insulin
By Brand
Humalog
Novolog
Apidra
Humulin R
Novolin R
Humulin N
Novolin N
Levemir
Lantus
Humalog Mix
Novolog Mix
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Latin America
By Country:
Brazil
Argentina
Mexico
Rest of Latin America
By Product Type:
Rapid-Acting Human Insulin
Short-Acting Human Insulin
Intermediate-Acting Human Insulin
Long-Acting Human Insulin
Premixed Human Insulin
By Brand
Humalog
Novolog
Apidra
Humulin R
Novolin R
Humulin N
Novolin N
Levemir
Lantus
Humalog Mix
Novolog Mix
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Africa
By Country:
South Africa
Central Africa
North Africa
By Product Type:
Rapid-Acting Human Insulin
Short-Acting Human Insulin
Intermediate-Acting Human Insulin
Long-Acting Human Insulin
Premixed Human Insulin
By Brand
Humalog
Novolog
Apidra
Humulin R
Novolin R
Humulin N
Novolin N
Levemir
Lantus
Humalog Mix
Novolog Mix
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Company Profiles
Novo Nordisk A/S *
Company Overview
Product Portfolio
Financial Performance
Recent Developments
Strategies
Eli Lilly and Company
Sanofi S.A.
Julphar Gulf Pharmaceutical Industries
Biocon Limited
Bioton S.A.
Gan & Lee Pharmaceuticals, Ltd.
Zhuhai United Laboratories Co., Ltd.
Wanbang Biopharmaceuticals Co., Ltd.
Dongbao Enterprise Group Co., Ltd.
“*” marked represents similar segmentation in other categories in the respective section.